SOURCE: StockCall


September 01, 2011 08:05 ET

Equity Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Sector's Relationship With the FDA

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Sep 1, 2011) - offers investors comprehensive research on the Drug Delivery industry and has completed analytical research on Alkermes Inc. (NASDAQ: ALKS) and Hospira Inc. (NYSE: HSP). Register with us today at to have free access to these researches.

It seems unlikely that any investor would argue for the total dissolution of the Food and Drug Administration. Its services ensure the safety and efficacy of drugs that end up on the market. Still, companies in the Drug Delivery sector can often have strained relationships with the ruling body, as it holds a great deal of power over whether certain products ever return profits. This can make companies relying on the performance of a single drug somewhat risky. Register now at to have free access to our reports on the Drug Delivery industry. is an online platform where investors doing their due-diligence on the Drug Delivery industry can have easy and free access to our analyst research and opinions on Alkermes Inc. and Hospira Inc.; investors and shareholders of these companies can simply register for a complimentary membership at

Many companies in the sector have been working towards approvals lately. Alkermes Inc. feels confident its diabetes drug Bydureon is on the way to FDA approval after completing an additional study requested by the administration. Alkermes Inc. research report is accessible for free by registering today at

Conversely, Hospira Inc. also recently received approval of a new oncology drug, gemcitabine injection which is expected to hit the market in September. Hospira has been struggling due to some manufacturing issues after the company received a notice from the FDA about unsatisfactory operations back in April. Hospira Inc. research report is available for free by signing up now at

As FDA approval is always necessary for the monetization of drugs, investors should keep a close eye on approval announcements if they want to hit it big in this space. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information